NBL-CY01-P
Cytokine-Engineered Biologics for Angiogenesis
NBL-CY01-P is an engineered cytokine therapy designed to stimulate angiogenesis and reduce inflammation in ischemic vascular diseases. By enhancing IL-4/IL-13 pathways, this novel biologic promotes blood vessel growth and tissue repair without the need for cell transplantation. As an off-the-shelf injectable, NBL-CY01-P offers a scalable, cell-free alternative for treating conditions such as PAD, diabetic ulcers, and myocardial ischemia.
Indication
Ischemic vascular diseases beyond PAD/CLI (e.g., diabetic foot ulcer, myocardial ischemia).
Technology
Self-engineered cytokines as standalone or combination biologics to boost angiogenesis and reduce inflammation. Off-the-shelf and scalable
Format
Homologous injection